News Headlines Article

After cancer drug trials crash, Peninsula biotech sheds one-third of jobs
San Francisco Business Times

Threshold Pharmaceuticals Inc. will lay off 20 to 25 people — or 30 percent to 40 percent of its staff — to focus on mid-stage trials of one potential cancer-fighting drug after another experimental cancer drug failed two late-stage studies. The South San Francisco company (NASDAQ: THLD) will take a one-time severance-related charge of about $2.6 million, most of which will be paid by the end of the first quarter, it said in a Securities and Exchange Commission filing …